Caprolactam Chemicals returned to profitability in the financial year ended March 31, 2026, reporting a net profit of ₹176.12 lakh compared to a net loss of ₹70.87 lakh in the prior year. Revenue from operations rose 56.7% to ₹1,055.75 lakh from ₹673.96 lakh, underpinned by improved operational efficiency and market demand. For the quarter ended March 31, 2026, the company posted a net profit of ₹83.76 lakh on revenue of ₹306.70 lakh.

The Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026. The statutory auditors, Pulindra Patel & Co., issued an unmodified opinion on the results, confirming compliance with Indian Accounting Standards (Ind AS) and SEBI Listing Regulations. Additionally, the Board appointed M/s. Shrey Pandey & Associates as the internal auditor for the financial year 2026-27.

Total income for FY26 stood at ₹1,058.86 lakh, a significant increase from ₹674.92 lakh in the previous year. The company successfully managed its expenses, which totaled ₹842.29 lakh, up from ₹743.29 lakh in FY25, resulting in a profit before tax of ₹216.57 lakh. This marks a turnaround from the loss before tax of ₹68.37 lakh reported in the preceding year.

Financial Performance

The balance sheet reflects a strengthening of the financial position, with total assets growing to ₹1,703.96 lakh as of March 31, 2026, from ₹1,428.42 lakh a year earlier. Equity increased to ₹658.16 lakh from ₹482.87 lakh, bolstered by the retained earnings from the profitable year. Trade receivables rose to ₹621.18 lakh, indicating higher sales volumes, while borrowings stood at ₹922.90 lakh.

Cash flow from operating activities improved to a net generation of ₹164.97 lakh for FY26, compared to a net outflow of ₹56.18 lakh in the previous year. This positive operational cash flow supported investing activities, primarily the purchase of property, plant, and equipment amounting to ₹146.78 lakh. Cash and cash equivalents at the end of the year stood at ₹8.69 lakh.

Caprolactam Chemicals Limited has informed the BSE of an upcoming board meeting scheduled for May 30, 2026, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting has been convened to consider, approve, and take on record the audited financial results along with the audit report of the statutory auditor for the quarter and financial year ended March 31, 2026. The intimation was filed on May 6, 2026, and has also been uploaded on the company's official website.

Board Meeting Details

The following key details pertain to the scheduled board meeting:

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has also disclosed the status of its trading window for dealing in its securities. The trading window has been closed effective April 1, 2026, and will remain closed until 48 hours after the public announcement of the audited financial results. This measure is in compliance with applicable insider trading regulations and is intended to restrict trading by designated persons during the period leading up to the results announcement.

Signatory Details

The board meeting intimation has been signed by Zaver Shankarlal Bhanushali, Managing Director of Caprolactam Chemicals Limited (DIN: 00663374). The communication has been addressed to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai 400 001, and the company has requested the exchange to inform its members accordingly.